Serum sST2 levels predict severe exacerbation of asthma

Respiratory Research

Toshiya Inui¹  Hajime Takizawa¹  Daisuke Kurai¹  Masaki Tamura¹  Masato Watanabe¹  Keitaro Nakamoto¹  Takeshi Saraya¹  Haruyuki Ishii¹  Yukari Ogawa¹  Kojiro Honda¹  Mitsuru Sada¹  Takuma Yokoyama¹ 

[1] Department of Respiratory Medicine, Kyorin University School of Medicine;

关键词: IL-33;    ST2L;    Biomarker;   

DOI  :  10.1186/s12931-018-0872-2

来源: DOAJ

【 摘 要 】

Abstract Background Neutrophilic inflammation is associated with poorly controlled asthma. Serum levels of sST2, a soluble IL-33 receptor, increase in neutrophilic lung diseases. We hypothesized that high serum sST2 levels in stable asthmatics are a predictor for exacerbation within a short duration. Methods This prospective observational study evaluated the serum sST2 levels of 104 asthmatic patients who were treated by a lung disease specialist with follow-ups for 3 months. Results High serum sST2 levels (> 18 ng/ml) predicted severe asthma exacerbation within 3 months. Serum sST2 levels correlated positively with asthma severity (treatment step), airway H2O2 levels, and serum IL-8 levels. High serum sST2 levels and blood neutrophilia (> 6000 /μl) were independent predictors of exacerbation. We defined a post-hoc exacerbation-risk score combining high serum sST2 level and blood neutrophilia, which stratified patients into four groups. The score predicted exacerbation-risk with an area under curve of 0.91 in the receiver operating characteristic curve analysis. Patients with the highest scores had the most severe phenotype, with 85.7% showing exacerbation, airflow limitation, and corticosteroid-insensitivity. Conclusions High serum sST2 levels predicted exacerbation within the general asthmatic population and, when combined with blood neutrophil levels, provided an exacerbation-risk score that was an accurate predictor of exacerbation occurring within 3 months.

【 授权许可】

Unknown